Alnylam Pharmaceuticals, Inc. · Cambridge, MA United States (NASDAQ: ALNY)
| 300 3rd St., 3rd Fl. | Phone: 617-551-8200 |
| Cambridge, MA | Fax: 617-551-8101 |
| 02142 | |
| United States | 
Map This Company |
Alnylam Pharmaceuticals, Inc. Rankings
| Russell 2000 (June 2011) |
More Companies in These Related Industries: Pharmaceutical Preparation MfgCompany Description
Call it The Silence of the Genes. Alnylam Pharmaceuticals runs interference with RNA to prevent disease. RNA interference (RNAi) technology developed by the biotech firm can selectively shut off harmful genes. The company is developing a pipeline of candidates both individually and through collaborations with other drugmakers. Its disease targets include rare genetic disorder ATTR (transthyretin-mediated amyloidosis) and RSV (respiratory syncytial virus), a common childhood viral infection. Additional R&D programs target neurological disorders, cardiovascular conditions, and cancers. Alnylam has R&D alliances and licensing agreements with companies including
Alnylam Pharmaceuticals, Inc. Reports
No subscription, no problem.
Download presentation-ready reports. From company profiles to the competitive landscape, Hoover's offers immediate access to individual reports.
Financials
| Company Type | Public - NASDAQ: ALNY Headquarters |
|---|---|
| Fiscal Year-End | December |
| 2011 Employees | 116 |
Executives
39 executives listed for Alnylam Pharmaceuticals, Inc. 's Cambridge, MA location.
| Chairman | John Clarke | |
|---|---|---|
| CEO and Director | John Maraganore | |
| President and COO | Barry Greene |